Lower antidepressant response to fluoxetine is associated with anxiety-like behavior, hippocampal oxidative imbalance, and increase on peripheral IL-17 and IFN-γ levels

Major depression is a leading contributor to the global burden of disease. This is mainly related to the disorder chronic and recurrent nature, and to high rates of refractoriness to treatment. Limited efficacy with currently available antidepressants highlights the need for more effective options for treating drug-resistant patients and emphasizes the importance of developing specific preclinical models for treatment-resistant populations. Treatment-resistant depression (TRD) is commonly defined as failure to respond to two or more trials of antidepressants. In this study, we investigated the effect of fluoxetine treatment for fourteen days on the depressive-like behavior and the oxidative and inflammatory parameters of mice submitted to chronic corticosterone administration. After 21 days of subcutaneous corticosterone administration (20mg/Kg/day) and 14 days of oral fluoxetine treatment (10mg/Kg/day, started on day 7 of induction protocol), we separated animals into two groups according to the tail suspension test's (TST) results: antidepressant responders (good response to antidepressant, GRA) and non-responders (resistance to antidepressant, AR). Forced swimming test (FST), elevated plus maze test (EPMT), and open field test (OFT) were performed. We found that animals classified as AR (i.e., those with higher immobility values in the TST) demonstrated anxiety-like behavior in the EPMT, increased H2O2 levels, and decreased catalase activity in the hippocampus, as well as increased serum levels of IL-17 and IFN-γ. Our findings suggest that a redox imbalance in the hippocampus, combined with increased levels of peripheral IL-17 and INF-γ, may be involved with an impaired response to fluoxetine.

[1]  A. Cleare,et al.  Comparison of hypothalamo-pituitary-adrenal function in treatment resistant unipolar and bipolar depression , 2021, Translational Psychiatry.

[2]  Wanlin Dai,et al.  Th17 Cells in Depression: Are They Crucial for the Antidepressant Effect of Ketamine? , 2021, Frontiers in Pharmacology.

[3]  A. Young,et al.  Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial , 2021, Neuropsychopharmacology.

[4]  Y. Tong,et al.  Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a/SYK/NF-κB axis , 2021, Journal of Neuroinflammation.

[5]  N. Waszkiewicz,et al.  Peripheral Markers of Depression , 2020, Journal of clinical medicine.

[6]  A. Carvalho,et al.  Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders , 2020, Translational Psychiatry.

[7]  Jian Liu,et al.  Neuroprotective Effects of Fluoxetine Against Chronic Stress-Induced Neural Inflammation and Apoptosis: Involvement of the p38 Activity , 2020, Frontiers in Physiology.

[8]  G. Bochi,et al.  Apocynin as an antidepressant agent: in vivo behavior and oxidative parameters modulation , 2020, Behavioural Brain Research.

[9]  C. Niolu,et al.  Vitamin D and N-Acetyl cysteine supplementation in treatment resistant depressive disorder patients: a general review. , 2020, Current pharmaceutical design.

[10]  O. Howes,et al.  Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls , 2020, Brain, Behavior, and Immunity.

[11]  K. Lohr,et al.  Defining treatment‐resistant depression , 2020, Depression and Anxiety.

[12]  A. Sartorius,et al.  Cytokine-mediated cellular immune activation in electroconvulsive therapy: A CSF study in patients with treatment-resistant depression , 2020, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[13]  C. Tamminga,et al.  Molecular adaptations of the blood–brain barrier promote stress resilience vs. depression , 2020, Proceedings of the National Academy of Sciences.

[14]  D. Blumberger,et al.  Management of Treatment-Resistant Depression: Challenges and Strategies , 2020, Neuropsychiatric disease and treatment.

[15]  A. Young,et al.  Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis , 2019, European Neuropsychopharmacology.

[16]  C. Pariante,et al.  Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis , 2019, Front. Psychiatry.

[17]  Xiaoyan Qin,et al.  2,3,5,4′-Tetrahydroxystilbene-2-O-beta-D-glucoside Reverses Stress-Induced Depression via Inflammatory and Oxidative Stress Pathways , 2018, Oxidative medicine and cellular longevity.

[18]  A. Camargo,et al.  Cholecalciferol counteracts depressive‐like behavior and oxidative stress induced by repeated corticosterone treatment in mice , 2018, European journal of pharmacology.

[19]  Wen-juan Lin,et al.  Blocking p38 Signaling Reduces the Activation of Pro-inflammatory Cytokines and the Phosphorylation of p38 in the Habenula and Reverses Depressive-Like Behaviors Induced by Neuroinflammation , 2018, Front. Pharmacol..

[20]  V. Naidu,et al.  Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice , 2018, Behavioural Brain Research.

[21]  N. Galvão-Coelho,et al.  Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls , 2018, Front. Psychiatry.

[22]  M. Maes,et al.  Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia , 2017, Neurotoxicity Research.

[23]  M. Trivedi,et al.  Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection , 2017, Brain, Behavior, and Immunity.

[24]  M. Maes,et al.  Brain antioxidant effect of mirtazapine and reversal of sedation by its combination with alpha-lipoic acid in a model of depression induced by corticosterone. , 2017, Journal of affective disorders.

[25]  V. Prado,et al.  Reduced Vesicular Acetylcholine Transporter favors antidepressant behaviors and modulates serotonin and dopamine in female mouse brain , 2017, Behavioural Brain Research.

[26]  K. Su,et al.  Recurrence of depressive disorders after interferon-induced depression , 2017, Translational Psychiatry.

[27]  S. Kasper,et al.  Evidence-based pharmacotherapy of treatment-resistant unipolar depression , 2017, International journal of psychiatry in clinical practice.

[28]  S. Salim,et al.  Oxidative Stress and the Central Nervous System , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[29]  Andrew H. Miller,et al.  The role of inflammation in depression: from evolutionary imperative to modern treatment target , 2015, Nature Reviews Immunology.

[30]  T. Liu,et al.  A Meta-Analysis of Oxidative Stress Markers in Depression , 2015, PloS one.

[31]  A. Danese,et al.  Inflammation and clinical response to treatment in depression: A meta-analysis , 2015, European Neuropsychopharmacology.

[32]  G. Alves,et al.  Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review , 2015, Current neuropharmacology.

[33]  S. King,et al.  Rodent models of treatment-resistant depression. , 2015, European journal of pharmacology.

[34]  S. Vanner,et al.  Participation of interleukin 17A in neuroimmune interactions , 2014, Brain, Behavior, and Immunity.

[35]  Jonathan Cueto-Escobedo,et al.  Myristic Acid Produces Anxiolytic-Like Effects in Wistar Rats in the Elevated Plus Maze , 2014, BioMed research international.

[36]  R. McIntyre,et al.  Inflamed moods: A review of the interactions between inflammation and mood disorders , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[37]  B. Samuels,et al.  Mechanisms underlying the antidepressant response and treatment resistance , 2014, Front. Behav. Neurosci..

[38]  Michael Maes,et al.  Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. , 2014, Current pharmaceutical design.

[39]  A. Carvalho,et al.  The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives , 2014, Psychotherapy and Psychosomatics.

[40]  S. Salim,et al.  Depression, anxiety-like behavior and memory impairment are associated with increased oxidative stress and inflammation in a rat model of social stress , 2013, Brain Research.

[41]  S. M. Oliveira,et al.  Transient receptor potential ankyrin 1 receptor stimulation by hydrogen peroxide is critical to trigger pain during monosodium urate-induced inflammation in rodents. , 2013, Arthritis and rheumatism.

[42]  K. Kirkby,et al.  Cytokines as biomarkers in depressive disorder: Current standing and prospects , 2013, International review of psychiatry.

[43]  Andrea Cipriani,et al.  Fluoxetine versus other types of pharmacotherapy for depression. , 2013, The Cochrane database of systematic reviews.

[44]  O. Wolkowitz,et al.  Dysregulated relationship of inflammation and oxidative stress in major depression , 2013, Brain, Behavior, and Immunity.

[45]  P. Renshaw,et al.  Factors influencing behavior in the forced swim test , 2013, Physiology & Behavior.

[46]  M. Cheng,et al.  Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior , 2013, Psychoneuroendocrinology.

[47]  L. Harrington,et al.  Inflammatory T Helper 17 Cells Promote Depression-like Behavior in Mice , 2013, Biological Psychiatry.

[48]  R. Hen,et al.  Modeling treatment-resistant depression , 2011, Neuropharmacology.

[49]  Cai Song,et al.  Cytokines mediated inflammation and decreased neurogenesis in animal models of depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[50]  J. Kipnis,et al.  Regulation of learning and memory by meningeal immunity: a key role for IL-4 , 2010, The Journal of experimental medicine.

[51]  T. Messer,et al.  Therapieresistente Depressionen , 2009, Fortschritte der Neurologie-Psychiatrie.

[52]  R. Yoshimura,et al.  Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  M. Maj,et al.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression , 2009, Metabolic Brain Disease.

[54]  D. F. Drake,et al.  Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression , 2009, Biological Psychiatry.

[55]  Scott J. Russo,et al.  Molecular Adaptations Underlying Susceptibility and Resistance to Social Defeat in Brain Reward Regions , 2007, Cell.

[56]  A. Rush The varied clinical presentations of major depressive disorder. , 2007, The Journal of clinical psychiatry.

[57]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[58]  Danielle L. Graham,et al.  Essential Role of BDNF in the Mesolimbic Dopamine Pathway in Social Defeat Stress , 2006, Science.

[59]  Ove Wiborg,et al.  Hippocampal Cytogenesis Correlates to Escitalopram-Mediated Recovery in a Chronic Mild Stress Rat Model of Depression , 2006, Neuropsychopharmacology.

[60]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[61]  C. Belzung,et al.  The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. , 2003, European journal of pharmacology.

[62]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[63]  A K Manatunga,et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. , 2001, The New England journal of medicine.

[64]  M. Brandão,et al.  Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze , 1997, Behavioural pharmacology.

[65]  R. Porsolt,et al.  Depression: a new animal model sensitive to antidepressant treatments , 1977, Nature.

[66]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[67]  I. Fridovich,et al.  The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. , 1972, The Journal of biological chemistry.

[68]  A. Phaniendra,et al.  Free Radicals: Properties, Sources, Targets, and Their Implication in Various Diseases , 2014, Indian Journal of Clinical Biochemistry.

[69]  Andrew H. Miller,et al.  Cytokines sing the blues: inflammation and the pathogenesis of depression. , 2006, Trends in immunology.

[70]  B. Thierry,et al.  The tail suspension test: A new method for screening antidepressants in mice , 2004, Psychopharmacology.

[71]  H. Aebi,et al.  Catalase in vitro. , 1984, Methods in enzymology.